Thomas P. Leist, MD, PhD

Thomas P. Leist, MD, PhD

Contact Dr. Leist

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-6871
(215) 503-2990 fax

Most Recent Peer-reviewed Publications

  1. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
  2. Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis
  3. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis
  4. Cladribine tablets added to IFN-β in active relapsing MS
  5. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis
  6. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
  7. Erratum: Psychometri cvalidation of the Fatigue Symptoms and Impacts Questionnaire-Relapsing Multiple Sclerosis(FSIQ-RMSTM).(Valuein Health (2015) 18(A26))
  8. Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse
  9. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-β therapy
  10. Therapy optimization in multiple sclerosis: A prospective observational study of therapy compliance and outcomes
  11. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial
  12. Relevance of MOA in MS treatment efficacy
  13. Case scenario #2
  14. Case scenario #1
  15. Novel Therapeutics in Multiple Sclerosis Management: Clinical Applications
  16. Multitasking in multiple sclerosis: Can it inform vocational functioning?
  17. Cladribine: Mode of action and implications for treatment of multiple sclerosis
  18. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
  19. Human optic nerve DTI with EPI geometric distortion correction
  20. Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis